Biomarin Pharmaceutical Inc (BMRN)

Total asset turnover

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Revenue (ttm)	US$ in thousands	2,443,023	2,373,030	2,261,604	2,184,719	2,123,138	2,059,481	1,999,471	1,903,678	1,871,615	1,827,451	1,829,463	1,891,778	1,815,339	1,822,817	1,822,364	1,813,337	1,772,797	1,694,305	1,597,556	1,518,971
Total assets	US$ in thousands	6,872,670	6,841,600	6,758,160	6,563,170	6,433,700	6,375,070	6,264,040	6,145,840	6,062,710	6,004,770	5,977,480	5,898,500	5,805,050	5,848,020	6,158,090	5,302,110	4,722,840	4,690,040	4,558,130	4,393,380
Total asset turnover		0.36	0.35	0.33	0.33	0.33	0.32	0.32	0.31	0.31	0.30	0.31	0.32	0.31	0.31	0.30	0.34	0.38	0.36	0.35	0.35

March 31, 2024 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $2,443,023K ÷ $6,872,670K
= 0.36

The total asset turnover of Biomarin Pharmaceutical Inc has shown consistency in the range of 0.30 to 0.38 over the past few quarters. This ratio indicates that, on average, the company generates revenue of approximately 31% to 38% for each dollar of total assets it holds. The stability of this metric suggests that Biomarin Pharmaceutical Inc efficiently utilizes its assets to generate revenue. However, it is essential to monitor any fluctuations in this ratio over time to assess the company's operational efficiency and asset management strategies. Overall, the total asset turnover ratio reflects Biomarin Pharmaceutical Inc's effectiveness in generating sales relative to its total asset base.